Drug intelligence / Profile preview

stallimycin

Development stage
Discontinued
Lead developer
Farmitalia
Modality
Small Molecules, Peptides
Administration
Topical
01

Overview

Stallimycin (distamycin A) is a natural polypyrrole oligopeptide antibiotic originally isolated from *Streptomyces distallicus*. It is a well-characterized DNA minor groove binding agent with a high preference for AT-rich sequences (typically four to five base pairs). By binding non-covalently to the minor groove, it displaces water molecules and interferes with the binding of transcription factors and the activity of DNA-dependent enzymes, such as RNA and DNA polymerases. Historically developed by Farmitalia, it was marketed topically for the treatment of herpes simplex infections under the name stallimycin. However, due to systemic toxicity and the advent of more effective agents, its clinical use is now largely obsolete, and it is primarily employed as a research tool in molecular biology to study DNA-ligand interactions and as a template for designing sequence-specific DNA-binding drugs.

Brand names
Herperal
Other names
distamycindistamycin Adistallimycin
02

Targets

DNA minor groove (A/T-rich tracts)DNA minor groove (G/C-containing or mixed sequences)

Beyond the preview

Go deeper on stallimycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on stallimycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call